Eli Lilly and Company LLY
Set alert
At close · Oct 30
After hours · Oct 30, 7:59 PM ET
- YTD
- +31.90%
- 1 year
- +67.86%
- Open
- 1,428.83
- Prev close
- 1,373.70
- Mkt cap
- 1.26T
- Vol
- 5.03M
- Avg vol
- 2.55M
- EPS
- 30.81
- P/E
- 46.01
- Div yield
- 0.50%
More statistics
- Low
- 1,409.00
- High
- 1,449.68
- Forward P/E
- 28.70
- Beta
- 0.00
- Short ratio
- 3.00
- Inst. own
- 85.39%
- Dividend
- 6.92
- Ex-div date
- Nov 12, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 1,193.68
- 200-d avg
- 1,089.52
- 1y target
- 1,377.71
5D chart
Events in this range
- Oct 29, 2026Earnings: 7.48; estimate 5.71; surprise 31%
- Oct 30, 2026Rating: Argus Research · Buy → Buy
- Oct 30, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 30, 2026Rating: Truist Securities · Buy → Buy
- Oct 30, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 30, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 30, 2026Rating: Scotiabank · Sector Outperform → Sector Outperform
Signals (175)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:25 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 1:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| RSI: Overbought | Oct 30, 11:05 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 4 days ago |
| RSI: Overbought | Oct 28, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:00 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:15 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 2:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:35 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:20 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 11:10 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:00 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:20 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:05 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:00 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 6 days ago |
News
1 day ago fool.com
After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?
Eli Lilly dominates the weight loss drug market and has a strong pipeline that may produce future winners. The company's stock has climbed amid optimism about this portfolio and its impact on…
1 day ago 247wallst.com
$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%
A single health care ETF launched two decades ago at rock-bottom cost has quietly compounded into a sum that surprises most investors, but whether its three closest rivals can match it depends…
1 day ago fool.com
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030
Eli Lilly stock has been on a tear, averaging annual gains of more than 30%. Future growth rates may not be quite so high, though.
1 day ago benzinga.com
Elon Musk Says Eli Lilly Has ‘Some Banger Drugs Coming Out’ After CEO Dave Ricks Bets Against Vinod Khosla's Big Biotech Skepticism
Elon Musk praises Eli Lilly’s upcoming drug pipeline as CEO Dave Ricks responds to skepticism about innovation at big biotech companies.
2 days ago marketbeat.com
What Eli Lilly and Company (LLY) Said on Its Q3 Earnings Call
Eli Lilly and Company NYSE: LLY raised its full-year outlook after reporting third-quarter revenue growth of 39% from the prior-year period, driven primarily by demand for its Mounjaro and Zepbound…
-
2 days ago benzinga.com
JP Morgan Maintains Overweight on Eli Lilly, Raises Price Target to $1650
JP Morgan analyst Chris Schott maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1500 to $1650.
-
2 days ago benzinga.com
Scotiabank Maintains Sector Outperform on Eli Lilly, Raises Price Target to $1605
Scotiabank analyst Louise Chen maintains Eli Lilly (NYSE:LLY) with a Sector Outperform and raises the price target from $1300 to $1605.
-
2 days ago benzinga.com
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1596
Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1430 to $1596.
2 days ago benzinga.com
Eli Lilly 'Deserves' Stock Upside: Analyst
Eli Lilly beats Q3 estimates on Mounjaro and Zepbound growth. Analysts lift price targets as 2026 revenue guidance jumps to $92 billion.
2 days ago 247wallst.com
Eli Lilly's Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs
Mounjaro and Zepbound built Lilly into a trillion-dollar company, but a surge in oncology, immunology, and neuroscience revenue hints that the real growth story is just getting started.
-
2 days ago benzinga.com
Wells Fargo Maintains Overweight on Eli Lilly, Raises Price Target to $1500
Wells Fargo analyst Mohit Bansal maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1330 to $1500.
-
2 days ago benzinga.com
RBC Capital Maintains Outperform on Eli Lilly, Raises Price Target to $1600
RBC Capital analyst Trung Huynh maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1500 to $1600.
-
2 days ago benzinga.com
Truist Securities Reiterates Buy on Eli Lilly, Raises Price Target to $1612
Truist Securities analyst Srikripa Devarakonda reiterates Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1376 to $1612.
2 days ago zacks.com
LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug Growth
Eli Lilly raises its 2026 revenue outlook as Mounjaro and Zepbound sales surge, Medicare access expands and Foundayo gains traction despite pricing pressures.
2 days ago benzinga.com
Defensives Lead Sectors In Friday Trading As Growth Trails
Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
-
2 days ago benzinga.com
Argus Research Maintains Buy on Eli Lilly, Raises Price Target to $1550
Argus Research analyst Jasper Hellweg maintains Eli Lilly (NYSE:LLY) with a Buy and raises the price target from $1300 to $1550.
2 days ago benzinga.com
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed as AMZN, INTC Slide After Q3 Earnings—DELL, LLY, AZN in Focus (UPDATED)
U.S. stock were mixed on Friday, as the Dow Jones, S&P 500, and Nasdaq 100 index futures moved in different direction.
2 days ago benzinga.com
LLY Stock Hits Record as CEO Says Middle-Income Consumers Are Driving Pharma’s ‘Largest New Category Expansion’
Eli Lilly stock hits a record close as CEO David Ricks points to middle-income demand and a historic pharma category expansion.
2 days ago seekingalpha.com
Eli Lilly: The Bar Just Got Higher
Eli Lilly delivered standout 3Q26 results, with 39% revenue growth to $24.4B, driven by Mounjaro and Zepbound franchises. LLY's growth story is increasingly diversified, with Foundayo, Retatrutide,…
3 days ago seekingalpha.com
Eli Lilly and Company (LLY) Q3 2026 Earnings Call Transcript
Eli Lilly and Company ( LLY ) Q3 2026 Earnings Call October 29, 2026 10:00 AM EDT Company Participants Mike Czapar - Senior Vice President of Investor Relations David Ricks - Chairman, President &…
3 days ago fool.com
Eli Lilly Sells 53% More at Lower Prices: Rapid Earnings Reaction
Eli Lilly's third-quarter revenue rose 39% to about $24.4 billion, as a 53% jump in volume more than offset a 15% drop in realized prices. Part of the quarter won't repeat, and deal charges are…
3 days ago nypost.com
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillion
Eli Lilly stock hit a record high Thursday thanks to a stronger-than-expected earnings report fueled by sales of weight loss drugs Monjuaro and Zepbound.
3 days ago seekingalpha.com
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
Eli Lilly and Company delivered solid third-quarter results. In Q3, LLY's non-GAAP EPS and revenue grew by 6.6% and 38.6% year-over-year, respectively. Mounjaro+Zepbound, Lilly's diabetes and obesity…
3 days ago zacks.com
LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised
Lilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion.
3 days ago benzinga.com
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
-
3 days ago benzinga.com
Eli Lilly and Company Reports $303M In Q3 2026 Special Charges, Bringing 9-Month Total To $1.3B, Primarily Driven By Intangible Asset Impairment, Acquisition Costs And Litigation
Note 5: Asset Impairment, Restructuring, and Other Special ChargesAsset impairment, restructuring, and other special charges recognized during the three and nine months ended September 30, 2026 were…
3 days ago zacks.com
GDP, PCE, Jobless Claims and Q3 Earnings - Busy Morning!
Headline PCE Price Index month over month reached +0.5%, in-line with expectations. Year over year, this came in at +3.6%.
3 days ago benzinga.com
Eli Lilly Q3 2026 Earnings Call Transcript
Eli Lilly (NYSE:LLY) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
3 days ago 247wallst.com
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher
Merck (NYSE:MRK | MRK Price Prediction) is the second big drugmaker to reward investors with an earnings beat and a raised profit outlook.
3 days ago zacks.com
Lilly (LLY) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall…
3 days ago benzinga.com
8 Of 11 Sectors Rise Thursday As Defensives Lead
Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
3 days ago benzinga.com
Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
3 days ago benzinga.com
Eli Lilly Mounjaro Clocks 65% Jump in Sales to Massive $10.7 billion
Eli Lilly tops Q3 forecasts on surging Mounjaro sales, raises 2026 revenue outlook to $92 billion, and hits new 52-week highs despite an EPS forecast trim.
3 days ago zacks.com
Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $7.48 per share, beating the Zacks Consensus Estimate of $5.38 per share. This compares to earnings of $7.02 per share a year ago.
3 days ago schaeffersresearch.com
Alphabet's Earnings Fumble Triggers Pre-Market Selloff
Stock futures are suffering steep pre-market losses after Alphabet (GOOGL) reported a grim third-quarter report
3 days ago invezz.com
Eli Lilly's blowout quarter has a $5.5 billion twist
Eli Lilly LLY reported better-than-expected earnings for its fiscal Q3 on Thursday, offering fresh evidence that helps justify its trillion-dollar market cap. Sales reached $24.4 billion, while…
3 days ago wsj.com
Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound
The pharmaceutical company's third-quarter profit came in at $6.45 billion, or $7.22 a share, compared with $5.58 billion, or $6.21 a share, a year earlier.
3 days ago barrons.com
Eli Lilly Stock Jumps as Monster Earnings Powered by Mounjaro and Zepbound
Eli Lilly posts earnings that handily top estimates, fueled by strong performance in its metabolic portfolio.
-
3 days ago benzinga.com
Eli Lilly Lowers FY2026 Adj EPS Guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 Est; Raises FY2026 Sales Guidance from $85.000B-$87.000B to $91.000B-$92.000B vs $88.848B Est
Eli Lilly (NYSE:LLY) lowers FY2026 Adj EPS guidance from $35.50-$36.50 to $35.00-$36.00 vs $34.04 analyst estimate. Raises FY2026 sales outlook from $85.000 billion-$87.000 billion to $91.000…
-
3 days ago benzinga.com
Eli Lilly Q3 Adj. EPS $7.48 Beats $6.50 Estimate, Sales $24.397B Beat $22.610B Estimate
Eli Lilly (NYSE:LLY) reported quarterly earnings of $7.48 per share which beat the analyst consensus estimate of $6.50 by 15.08 percent. This is a 6.55 percent increase over earnings of $7.02 per…
3 days ago reuters.com
Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Eli Lilly raised its full-year revenue forecast and beat third-quarter earnings expectations on Thursday, propelled by surging demand for injectable weight-loss drugs that could allay investor
3 days ago prnewswire.com
Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
Revenue in Q3 2026 increased 39% to $24.4 billion driven primarily by Mounjaro and Zepbound. Q3 revenue included approximately $900 million of benefits, primarily from $410 million of Jardiance…
3 days ago cnbc.com
Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue on Thursday. The results will likely be fueled by its blockbuster obesity drug Zepbound and diabetes counterpart Mounjaro.
3 days ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds dip to 47% as Wall Street weighs a tech selloff, Amazon earnings, PCE inflation, and cooling oil.
4 days ago benzinga.com
Dow Gains For Third Session Following Fed Decision: Investor Sentiment Improves, Greed Index Remains In ‘Fear’ Zone
U.S. stocks rose after the Fed held rates steady, but CNN's Fear & Greed Index improved to 36, remaining in the Fear zone.
4 days ago benzinga.com
Amazon, Alphabet and 3 Stocks to Watch Heading Into Thursday
Stocks in focus: Amazon and Eli Lilly report earnings; Alphabet missed estimates and fell 10%; Microsoft beat; Caterpillar reports today.
4 days ago benzinga.com
Eli Lilly Shares Trending On Retatrutide Win Ahead Of Earnings: What You Should Know
Eli Lilly shares rise 1.89% after hours following positive Phase 3 retatrutide diabetes trial results ahead of quarterly earnings.
4 days ago benzinga.com
Traders Are Pricing a 7% Swing in Amazon Ahead of Earnings
Amazon, Intel, Sandisk and six other stocks report earnings Thursday. See implied moves, analyst estimates and the billions in market value at stake.
4 days ago benzinga.com
Amazon, Eli Lilly On Deck Thursday As AWS Growth, Drug Demand Face Test
Amazon headlines Thursday’s reports, with investors focused on whether accelerating AWS growth and heavy AI spending can support the next leg of its expansion. Eli Lilly, Mastercard, Merck,…